MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 10-31-2025
Illumina Cash Conversion Cycle 2011-2026 | ILMN
Annual Cash Conversion Cycle Illumina
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 142 | 102 | 82.9 | 59.1 | - | 130 | 128 | 139 | 135 | - | 127 | 119 | 143 | 158 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 158 | 59.1 | 122 |
Quarterly Cash Conversion Cycle Illumina
| 2025-Q3 | 2025-Q2 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 157 | 150 | - | 139 | 143 | 128 | 121 | - | - | 96.7 | 80.7 | - | 92.1 | 94.4 | 47.4 | - | 144 | 185 | 144 | 54.9 | 132 | 135 | 130 | 54.1 | 127 | 129 | 124 | 48.2 | 121 | 126 | 121 | 59.2 | 117 | 109 | 66.8 | - | 128 | 121 | 112 | 51.5 | 122 | 126 | 118 | 56.3 | 111 | 123 | 133 | 63.4 | 163 | 167 | 147 | 58.4 | 170 | 141 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 185 | 47.4 | 114 |
Cash Conversion Cycle of other stocks in the Diagnostics research industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
50.2 | - | -6.23 % | $ 30.6 M |  Germany |
 |
ICON Public Limited Company
ICLR
|
62 | $ 98.33 | 0.9 % | $ 8.11 B |  Irlanda |
|
Akumin
AKU
|
36.1 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
-38.7 | - | -6.19 % | $ 10.5 M |  USA |
 |
Charles River Laboratories International
CRL
|
65 | $ 155.46 | 1.83 % | $ 7.71 B | USA |
 |
Bioventus
BVS
|
224 | $ 8.62 | 0.23 % | $ 574 M | USA |
 |
DexCom
DXCM
|
134 | $ 64.24 | -1.56 % | $ 25.1 B | USA |
 |
Castle Biosciences
CSTL
|
45.9 | $ 25.56 | 0.95 % | $ 710 M | USA |
 |
CareDx, Inc
CDNA
|
51.5 | $ 17.01 | 3.4 % | $ 906 M | USA |
 |
Accelerate Diagnostics
AXDX
|
364 | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
42.5 | $ 103.57 | 0.29 % | $ 19.5 B | USA |
 |
Guardant Health
GH
|
79.6 | $ 85.49 | 1.75 % | $ 10.7 B | USA |
 |
Global Cord Blood Corporation
CO
|
184 | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
11 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
142 | - | 0.12 % | $ 80.1 M | China |
 |
Fulgent Genetics
FLGT
|
42.4 | $ 14.77 | 0.61 % | $ 447 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.21 K | - | - | $ 10.7 B | USA |
|
Biodesix
BDSX
|
41.7 | $ 17.88 | -6.63 % | $ 2.32 B | USA |
 |
Anixa Biosciences
ANIX
|
275 | $ 2.83 | -1.05 % | $ 91.8 K | USA |
 |
Danaher Corporation
DHR
|
77.5 | $ 187.32 | 0.57 % | $ 134 B | USA |
 |
IQVIA Holdings
IQV
|
73.9 | $ 164.72 | 1.1 % | $ 28.3 B | USA |
 |
Biocept
BIOC
|
78.1 | - | -13.05 % | $ 7.29 M | USA |
 |
Heska Corporation
HSKA
|
138 | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
104 | - | -20.0 % | $ 1.06 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
39.5 | $ 199.7 | -0.46 % | $ 22.2 B | USA |
 |
QIAGEN N.V.
QGEN
|
122 | - | - | $ 10.6 B |  Niderland |
 |
Agilent Technologies
A
|
111 | $ 111.51 | -0.06 % | $ 33.9 B | USA |
 |
BioNano Genomics
BNGO
|
225 | $ 1.11 | -0.89 % | $ 1.41 M | USA |
 |
DarioHealth Corp.
DRIO
|
207 | $ 9.0 | -0.99 % | $ 255 M |  Israel |
 |
Neogen Corporation
NEOG
|
150 | $ 9.09 | -2.78 % | $ 1.97 B | USA |
 |
National Research Corporation
NRC
|
29.4 | $ 16.52 | 0.12 % | $ 370 M | USA |
 |
Chembio Diagnostics
CEMI
|
111 | - | 0.22 % | $ 16.8 M | USA |
 |
Pacific Biosciences of California
PACB
|
185 | $ 1.33 | 4.72 % | $ 399 M | USA |
 |
Co-Diagnostics
CODX
|
299 | - | - | $ 79.8 M | USA |
 |
Medpace Holdings
MEDP
|
50.4 | $ 450.41 | 1.48 % | $ 13 B | USA |
 |
DermTech
DMTK
|
66.7 | - | -11.32 % | $ 2.94 M | USA |
 |
Mettler-Toledo International
MTD
|
66.4 | $ 1 173.74 | 0.49 % | $ 24.2 B |  Schweiz |
 |
Personalis
PSNL
|
-11.5 | $ 6.72 | 1.97 % | $ 398 M | USA |
 |
NeoGenomics
NEO
|
82.4 | $ 7.88 | -1.25 % | $ 1.01 B | USA |
 |
Enzo Biochem
ENZ
|
154 | - | -8.98 % | $ 14.8 K | USA |
 |
Natera
NTRA
|
81.5 | $ 187.85 | -1.29 % | $ 18.5 B | USA |
 |
Sotera Health Company
SHC
|
33.5 | $ 13.42 | 0.71 % | $ 3.81 B | USA |
 |
Invitae Corporation
NVTA
|
299 | - | - | $ 21.2 M | USA |
 |
OPKO Health
OPK
|
242 | $ 1.19 | 2.59 % | $ 826 M | USA |